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Abstract
There is scant literature regarding the psychological 
effects of intravenous immunoglobulin (IVIG) treatment 
experience on quality of life (QOL) for neurological 
autoimmune disease patients diagnosed with multiple 
sclerosis, multifocal motor neuropathy, myasthenia 
gravis, and chronic inflammatory demyelinating 
polyneuropathy. IVIG treatment experience predicted 
QOL in 1 Neuro-QOL subscale; illness intrusiveness 
mediated 9 of the Neuro-QOL subscales using bias-
corrected bootstrapping for statistical significance; and 
personal control did not mediate the relationship 
between illness intrusiveness and QOL. 
Procedures
The sample was convenience/nonrandom, and
included 25 male and 54 female patients. Diagnoses 
were 30 MS, 25 CIDP, 13 MG, and 11 MMN.
Surveys included the IVIG experience visual analog 
scale, the IIRS scale, MHLC-Form C, and 10 Neuro-
QOL subscales. 
Data Analysis
Mediation analysis was used to estimate the 
coefficients of the model, analyze, and interpret the 
direct, indirect, and total effects (paths a, b, ab, c, c′). 
Bias-corrected bootstrap confidence intervals were 
estimated as well as effect sizes (Hayes, 2013). 
Noted in Table 1 are the results of mediation 
analyses of the 10 Neuro-QOL variables: 
satisfaction with social roles & activities, depression, 
fatigue, positive attitude & well-being, sleep, stigma, 
cognition, emotional & behavioral dyscontrol, lower 
extremity function, and upper extremity function.
Table 1
Research Questions
RQ1: Is the IVIG treatment experience (as measured 
by the Visual Analogue Scale) a significant predictor 
of QOL (as measured by 10 Neuro-QOL scales) in 
patients with autoimmune disorders who receive IVIG 
treatment?
RQ2: Does illness intrusiveness mediate the 
relationship between IVIG treatment experience and 
QOL (as measured by 10 Neuro-QOL scales) among 
individuals with autoimmune disease who received 
IVIG treatment?
RQ3: Does personal control mediate the relationship 
between illness intrusiveness and QOL (as measured 
by 10 Neuro-QOL scales) among individuals with 
autoimmune disease who receive IVIG treatment?
Purpose
The purpose of this quantitative, survey research study 
was to examine the relationship between the IVIG 
treatment experience (predictor variable) and QOL 
(outcome variable) in neurological autoimmune 
patients. Illness intrusiveness and personal control 
were studied as potential mediators.
Problem
IVIG (a purified blood product providing healthy 
antibodies) is the treatment of choice for the four 
neurological autoimmune diseases examined (MS, 
MMN, MG and CIDP). 
The high cost of the therapy, complicated 
schedules, and long hours of infusions may cause 
disruptions to the lives of the neurological autoimmune 
patients who receive it affecting illness 
intrusiveness. 
Illness intrusiveness has been shown to be a 
mediator in other chronic diseases (Dancey, Hutton-
Young, Moye, & Devins, 2002; Shawaryn et al., 2002). 
Control was examined as a mediator between illness 
intrusiveness and QOL which might shed light on why 
some patients may be more affected than others by 
the treatment.
Relevant Literature
The illness intrusiveness framework posits that 
disease and/or treatment factors affect illness 
intrusiveness which directly affects QOL. Illness 
intrusiveness is a mediating variable between the 
disease treatment and QOL (Devins, 2010). 
QOL is compromised and perception of control 
decreased when the disease treatment interferes with 
goals, interests, and enjoyable activities (Devins, 
2010; Poochikian-Sarkissian et al., 2008).
Treatment factors have been shown to be affiliated 
with increased illness intrusiveness (Bettazzoni et al., 
2008; Devins et al., 1990; Poochikian-Sarkissian et. 
al., 2008). 
Social Change Implications
This study expands research for immunoglobulin (Ig) 
therapy and serves to advance the practice of nursing 
and education, management, and clinical practice for 
patients receiving this treatment. 
Results from the study may provide insight for 
interventions to assist patients in adjusting to 
treatment.
Limitations
All 79 patients came from the same infusion center so 
generalizing to similar centers may be possible but a 
national population generalization may not be 
possible. 
Patients could not be randomly selected, but 
volunteered. Question #13 of the IIRS was 
inadvertently omitted from the survey given to 
participants. 
Results
RQ1: IVIG treatment experience significantly 
correlated with QOL PAWB.
RQ2: Illness intrusiveness mediated the relationship 
between IVIG treatment experience and 9 of the 
Neuro-QOL subscales.
RQ3: Personal control did not mediate illness 
intrusiveness and QOL.
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Conclusions
Findings show that how patients interpret or perceive 
the level of intrusiveness of IVIG influences their QOL. 
The indirect effects showed the more positive the IVIG 
experience the less the patient experienced illness 
intrusiveness and vice versa in 9 areas of QOL. Less 
illness intrusiveness indicated increased QOL.
The results may be helpful in identifying areas where 
IVIG patients deem the treatment experience 
interferes with their lifestyle. 
QOL
Outcomes
P - Value Variance 
Explained
Mediation/
Effect Size
SSRA p ˂ .001 46% Yes/
Medium
Depression p ˂ .001 33% Yes/
Medium
Fatigue p ˂ .001 39% Yes/
Medium
PAWB p ˂ .001 27% Yes/
Medium
Sleep p ˂ .001 36% Yes/
Medium
Stigma p ˂ .001 25% Yes/
Medium
Cognition p = .001 16% Yes/
Medium
EBD p < .001 20% Yes/
Medium
LEF P = .01 11% Yes/
Small
UEF p = .353 3% None
